Insulet Corp. Files Definitive Proxy Statement (DEF 14A)

Ticker: PODD · Form: DEF 14A · Filed: Apr 9, 2024 · CIK: 1145197

Insulet Corp DEF 14A Filing Summary
FieldDetail
CompanyInsulet Corp (PODD)
Form TypeDEF 14A
Filed DateApr 9, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$202 m, $4.6 million, $206.3 m, $1.7B
Sentimentbullish

Sentiment: bullish

Topics: Insulet, DEF 14A, Omnipod 5, Revenue Growth, Free Cash Flow

TL;DR

<b>Insulet Corp. achieved significant financial and operational milestones in 2023, driven by strong performance of its Omnipod 5 system, leading to 30% revenue growth and positive free cash flow.</b>

AI Summary

INSULET CORP (PODD) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. Insulet reported 30% revenue growth in 2023, driven by the Omnipod 5 automated insulin delivery (AID) system. The company achieved its eighth consecutive year of significant revenue growth. Omnipod 5 was the most prescribed AID system in the U.S. and contributed to a record number of new customer starts in 2023. Insulet became free cash flow positive in 2023 and significantly expanded margins. The company reached approximately 425,000 active global Omnipod customers, representing about 25% annual growth.

Why It Matters

For investors and stakeholders tracking INSULET CORP, this filing contains several important signals. The filing is a Definitive Proxy Statement (DEF 14A), indicating Insulet is seeking shareholder approval for matters typically related to annual meetings, such as director elections and executive compensation. The strong performance highlighted, particularly the success of Omnipod 5 and achieving free cash flow positivity, suggests a potentially favorable outlook for the company's strategic direction and financial health.

Risk Assessment

Risk Level: low — INSULET CORP shows low risk based on this filing. The filing is a routine DEF 14A, and the provided text focuses on positive historical performance and strategic successes, with no immediate negative indicators.

Analyst Insight

Review the full proxy statement for details on upcoming shareholder votes, executive compensation plans, and any forward-looking guidance or proposals that may impact future performance.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
N/A
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
30%

Revenue Breakdown

SegmentRevenueGrowth
Omnipod 5N/A30%

Key Numbers

  • 30% — Revenue Growth (Achieved in 2023)
  • 8 — Consecutive Years (Of significant revenue growth)
  • 425,000 — Active Global Omnipod Customers (Reached milestone)
  • 25% — Annual Growth (Of active global Omnipod customers)
  • 250,000 — Customers (Benefiting from Omnipod platform (partial data))

Key Players & Entities

  • INSULET CORP (company) — Filer name
  • Omnipod 5 (product) — Ground-breaking automated insulin delivery (AID) system
  • U.S. (location) — Market where Omnipod 5 was most prescribed AID system

FAQ

When did INSULET CORP file this DEF 14A?

INSULET CORP filed this Proxy Statement (DEF 14A) with the SEC on April 9, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by INSULET CORP (PODD).

Where can I read the original DEF 14A filing from INSULET CORP?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by INSULET CORP.

What are the key takeaways from INSULET CORP's DEF 14A?

INSULET CORP filed this DEF 14A on April 9, 2024. Key takeaways: Insulet reported 30% revenue growth in 2023, driven by the Omnipod 5 automated insulin delivery (AID) system.. The company achieved its eighth consecutive year of significant revenue growth.. Omnipod 5 was the most prescribed AID system in the U.S. and contributed to a record number of new customer starts in 2023..

Is INSULET CORP a risky investment based on this filing?

Based on this DEF 14A, INSULET CORP presents a relatively low-risk profile. The filing is a routine DEF 14A, and the provided text focuses on positive historical performance and strategic successes, with no immediate negative indicators.

What should investors do after reading INSULET CORP's DEF 14A?

Review the full proxy statement for details on upcoming shareholder votes, executive compensation plans, and any forward-looking guidance or proposals that may impact future performance. The overall sentiment from this filing is bullish.

Risk Factors

  • Competition in AID Technology [medium — market]: The company faces competition in the automated insulin delivery (AID) market, despite its leadership position with Omnipod 5.
  • Manufacturing and Supply Chain [medium — operational]: Continued success relies on effective manufacturing and supply chain operations to meet growing demand for Omnipod products.
  • Investment for Growth [low — financial]: Increased investments to drive long-term growth and operating leverage may impact short-term profitability.

Key Dates

  • 2024-05-22: Annual Meeting of Stockholders (implied) — Likely date for shareholder votes on proposals outlined in the proxy statement.
  • 2024-04-09: Filing Date — Date the DEF 14A was filed with the SEC.

Glossary

Automated Insulin Delivery (AID)
Systems that automatically deliver insulin based on continuous glucose monitoring data. (Central to Insulet's product strategy and growth, particularly Omnipod 5.)

Filing Stats: 4,391 words · 18 min read · ~15 pages · Grade level 15.5 · Accepted 2024-04-09 16:06:04

Key Financial Figures

  • $202 m — he prior year, our net income increased $202 million, from $4.6 million to $206.3 mill
  • $4.6 million — net income increased $202 million, from $4.6 million to $206.3 million, and our operating ma
  • $206.3 m — ased $202 million, from $4.6 million to $206.3 million, and our operating margin of 13%
  • $1.7B — REVENUE GROSS MARGIN OPERATING MARGIN $1.7B (30% growth) 68.3% (up 606 basis p

Filing Documents

Executive Compensation

Executive Compensation 6 Sustainability 7 Proposal 1 - Election of Directors 8 Governance of the Company 15 Our Board of Directors 15 Board Independence 15 Board Leadership Structure 15 Director Qualifications 15 Board Diversity 16 Board Refreshment and Director Skills Assessments 16 Meeting Attendance 17 Board Committees 17 Governance Policies and Procedures 19 Executive Sessions of Independent Directors 19 Succession Planning 19 Board and Committee Assessments 19 Risk Oversight 19 Director Overboarding Policy 19 Code of Conduct and Ethics 20 Clawback / Recoupment of Incentive Compensation 20 Stock Ownership Guidelines 20 Anti-Hedging and Anti-Pledging Policy 20 Majority Voting Policy for Uncontested Director Elections 20 Identifying and Evaluating Director Nominees 21 Recommendation of Director Nominees by Shareholders 21 Proxy Access 21 Communicating with the Board of Directors 21 Certain Relationships and Related Party Transactions 22

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 23 Executive Officers 25 Compensation Discussion and Analysis 28 Introduction 28 Executive Summary 28

Executive Compensation Philosophy

Executive Compensation Philosophy 29 Shareholder Engagement and Advisory "Say-on-Pay" Vote 30 2023 Compensation Elements and Decisions 30 Compensation Governance 40 Compensation Committee Report, Risk Assessment, and Pay Ratio 41 Compensation Committee Report 41 Compensation Risk Assessment 41 Pay Ratio Disclosure 41 TABLE OF CONTENTS

Executive Compensation Tables

Executive Compensation Tables 43 Summary Compensation Table 43 2023 Grants of Plan-Based Awards 44 Outstanding Equity Awards at 2023 Fiscal Year End 46 2023 Option Exercises and Stock Vested 47 Potential Payments Upon Termination or Change in Control 47 Pay versus Performance 51 Non-Employee Director Compensation 54 Proposal 2 - Non-Binding Advisory Vote to Approve Executive Compensation 56 Report of the Audit Committee of the Board of Directors 57 Matters Concerning Independent Registered Public Accounting Firm 58 Proposal 3 - Ratification Independent Registered Public Accounting Firm Appointment 59 General Information About the Meeting 60 Proposals to be Voted Upon 60 Attending the Annual Meeting 60 Submitting Questions at the Annual Meeting 60 Technical Assistance for the Annual Meeting 60 List of Shareholders Available 60 Recording of the Annual Meeting 61 Record Date and Voting Rights 61 Revocation of Proxies 61 Quorum; Abstentions; Broker Non-Votes 61 Vote Required 62 Solicitation of Proxies 62 Voting of Proxies 62 Other Business 62 Shareholder Proposals for 2025 Annual Meeting of Shareholders 63

Forward-Looking Statements

Forward-Looking Statements 63 Website References 63 Annex A Non-GAAP Reconciliation A-1 TABLE OF CONTENTS Proxy Statement Summary This proxy statement is furnished in connection with the solicitation of proxies by the Board of Directors of the Company for use at the Annual Meeting to be held on Wednesday, May 22, 2024, at 8:00 a.m., Eastern Time. The meeting will be held via live webcast at www.virtualshareholdermeeting.com/PODD2024 . The Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "10-K") containing financial statements for the fiscal year ended December 31, 2023, is being made available, together with this proxy statement, to shareholders at www.proxyvote.com . This summary highlights information related to topics discussed throughout this proxy statement. This summary does not contain all of the information that you should consider, and you should read the entire proxy statement carefully before voting. Attend our 2024 Annual Meeting of Shareholders Via Live Webcast Wednesday, May 22, 2024 8:00 a.m., Eastern Time Access to Live Webcast: www.virtualshareholdermeeting.com/PODD2024 How to Vote Prior to the Annual Meeting Vote by Mail Vote by Telephone Vote by Internet Cast your ballot, sign your proxy card and send by free post Dial toll-free 24/7 1-800-690-6903 Visit 24/7 www.proxyvote.com Complete, sign, and date your proxy card, and return it in the postage-paid envelope included in your proxy materials. Your proxy card must arrive by May 21, 2024. Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m., Eastern Time, on May 21, 2024. Have your proxy card in hand when you call and then follow the instructions. Use the internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m., Eastern Time, on May 21, 2024. Have your proxy card in hand when you access the website and follow the instructions to obtain your records and to

Executive Compensation

Executive Compensation Compensation Objectives and Mix We design and manage our compensation programs to align with our overall business strategy and to focus our employees on delivering sustained financial and operating results that drive long-term shareholder value. We believe it is important for our compensation programs to be competitive, maintain a performance and achievement-oriented culture, and align our executives' interests with those of our shareholders. The charts below illustrate, for fiscal 2023, the distribution of value among the three elements of direct compensation - base salary, target annual incentive awards and target long-term equity incentive awards -- for our Chief Executive Officer and, on average, for the other named executive officers. The components of the long-term equity incentive awards are also illustrated. Focus on Performance-Based, Long-Term Compensation . Of target total direct compensation, 93% of our Chief Executive Officer's compensation, and, on average, 81% of our other named executive officers' compensation was variable, either because it was subject to performance goals, or to fluctuations in stock price, or both. In addition, 84% of our Chief Executive Officer's target compensation was long-term, while 69% of the target annual compensation of our other named executive officers, on average, was long-term. Responsible Compensation Practices Our compensation programs and practices demonstrate our commitment to responsible pay and governance principles. We evaluate our compensation programs and practices regularly and we modify them to address evolving best practices. The following table highlights some of the practices we have adopted, and those we have avoided, to serve the long-term interests of our shareholders. What We Do What We Don't Do Solicit shareholder feedback on our programs No employment agreements with executives Set robust stock ownership guidelines No excise tax assistance (gross-ups) upon a cha

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.